Dacarbazine

Evidence Level: L5

Predicted Indications: 1

Dacarbazine

Pharmacist Assessment Report

Dacarbazine: From Hodgkin Lymphoma and Metastatic Melanoma to Upper Aerodigestive Tract Neoplasm

One-Sentence Summary

Dacarbazine is an alkylating chemotherapy drug originally used to treat Hodgkin lymphoma and metastatic melanoma. The TxGNN model predicts it may be effective for upper aerodigestive tract neoplasm, but no clinical trials are registered for this indication and the 19 publications retrieved are only indirectly related (melanoma, Hodgkin lymphoma, thyroid and other head and neck tumours).

Quick Overview

Item	Content
Original Indication	Hodgkin lymphoma (including classic Hodgkin lymphoma) and metastatic melanoma
Predicted New Indication	Upper aerodigestive tract neoplasm
TxGNN Prediction Score	0.9926
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacological knowledge, dacarbazine is a DNA-alkylating triazene agent. It is activated in the liver and produces a methylating species that damages DNA in rapidly dividing cells. Its efficacy in Hodgkin lymphoma and metastatic melanoma is established, and mechanistically it could plausibly act on other rapidly dividing tumours.

However, the data compiled for this report do not support a specific mechanistic rationale for upper aerodigestive tract neoplasms. These tumours are typically squamous cell carcinomas, which differ from the original indications. The very high TxGNN score is a computational prediction only.

The retrieved literature concerns related but distinct entities: melanoma (including mucosal and head and neck disease), Hodgkin lymphoma at head and neck sites, medullary thyroid carcinoma, and head and neck paragangliomas. These do not directly demonstrate dacarbazine efficacy in the predicted indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Selected from the retrieved publications. None directly tests dacarbazine in upper aerodigestive tract neoplasm.

PMID	Year	Type	Journal	Key Findings
41481311	2026	RCT (Phase 3)	JAMA Oncol	Toripalimab vs dacarbazine as first-line therapy in acral melanoma (MELATORCH); dacarbazine is the comparator, not the tested indication
7826911	1994	Clinical study	Ann Oncol	Dacarbazine plus 5-fluorouracil in advanced medullary thyroid cancer, a different tumour type
31621203	2019	Prospective observational	Cancer Med	Carbon-ion radiotherapy plus dacarbazine, nimustine and vincristine (DAV) in 21 patients with head and neck mucosal melanoma
11815960	2002	Preclinical	Cancer	Dacarbazine combined with radioimmunotherapy in medullary thyroid carcinoma xenografts in mice
20564093	2010	Cohort	Cancer	Characteristics and outcomes of Hodgkin lymphoma in head and neck sites
34654328	2024	Case series	Ear Nose Throat J	Six patients with head and neck malignant paragangliomas
20627492	2010	Review	Clin Oncol	Overview of medullary thyroid carcinoma management
12113649	2002	Review	Am J Clin Dermatol	Current concepts in melanoma management
20138008	2010	Review	Transfus Apher Sci	Hodgkin lymphoma in HIV-infected patients
12845209	2003	Case report	Onkologie	Mucosal metastases of malignant melanoma

India Market Information

Twenty valid single-ingredient injectable registrations exist; the approved indication text is not available for any of them. Five examples:

Authorization Number	Product Name	Dosage Form	Approved Indication
67481	Dacarex 500mg Injection	Vial of 1 injection	Not available
69542	Dtic Vhb 500mg Injection	Vial of 1 injection	Not available
63200	Dabaz 500 Injection	Vial of 1 powder for injection	Not available
172124	Oncodac 500mg Injection	Vial of 1 injection	Not available
252049	Zicarb 100mg Injection	Vial of 1 injection	Not available

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (alkylating agent, triazene class)
Myelosuppression Risk	High (knowledge-graph contraindication links include leukopenia, thrombocytopenia and anaemia)
Emetogenicity Classification	High
Monitoring Items	CBC with differential, liver and renal function
Handling Protection	Must follow cytotoxic drug handling regulations

Please also refer to the package insert warnings and precautions.

Safety Considerations

Contraindication-related conditions (not label text): kidney disease, liver disease, gallbladder disease, pyoureter, thrombocytopenia, anaemia, macrocytic anaemia, leukopenia, hepatic vein thrombosis, Budd-Chiari syndrome.
Drug Interactions: 233 interactions were identified. The main ones with a graded severity are naltrexone (Moderate) and levofloxacin (Minor). Others, such as pantoprazole, omeprazole, morphine, metformin, prednisone, simvastatin and ondansetron, have no severity grade assigned.

Please refer to the package insert for label-based warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a computational score alone. No clinical trials exist, and the literature does not address dacarbazine in upper aerodigestive tract squamous tumours. The drug also carries significant haematological, hepatic and renal safety concerns.

To proceed, the following is needed:

Package insert warnings and contraindications from the India registrations (currently a blocking gap for safety screening)
Detailed mechanism of action data (MOA) and a specific mechanistic rationale for this tumour type
Preclinical or clinical evidence of dacarbazine activity in upper aerodigestive tract neoplasms
Approved indication text for the Indian registrations
A comparison against current standard therapies for this indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.